...was president and CEO of cancer company Quanticel Pharmaceuticals Inc....

...patient selection technology. Co-founder and CEO Stephen Kaldor was president and CEO of cancer company Quanticel Pharmaceuticals Inc....

...Stafford and CSO James Veal, both of whom were senior executives at Versant portfolio company Quanticel Pharmaceuticals Inc....

...Stafford and CSO James Veal, both of whom were senior executives at Versant portfolio company Quanticel Pharmaceuticals Inc....

...LLC Eli Lilly and Co. (NYSE:LLY) Atlas Venture Neurology Single asset $18 ND 2011 2013 Quanticel Pharmaceuticals Inc....
...director at Versant. Versant has signed eight build-to-buys since its 2011 agreement with Celgene on Quanticel Pharmaceuticals Inc....

...Veal, who were both part of the senior management team at Versant’s first build-to-buy company, Quanticel Pharmaceuticals Inc....

...Jeffrey Stafford and CSO James Veal were on the management team at Versant-backed cancer company Quanticel Pharmaceuticals Inc....

...over which we transitioned the model and proved it with our returns.” Brad Bolzon, Versant Quanticel Pharmaceuticals Inc....

...wisely." The firm kicked off last week with news that Celgene is buying portfolio company Quanticel Pharmaceuticals Inc....

...2011 deal, which also gave Celgene an undisclosed equity stake (see BioCentury, Nov. 7, 2011). Quanticel Pharmaceuticals Inc....